1. The use of a compound representing 5- (2,6-dimorpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for the treatment of a disease, which is cancer or malignant neoplasm, which depends on the acquired phosphorylation and activation of AKT protein kinase during treatment with the mTOR inhibitor, which is everolimus. 2. The use according to claim 1, wherein the disease, which is a cancer or malignant neoplasm, is selected from breast cancer, renal cell carcinoma, tumors of the stomach, neuroendocrine tumors, lymphoma and prostate cancer. The use according to claim 1, wherein the disease, which is a cancer or malignant neoplasm, is selected from a benign or malignant tumor, cancer of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, tumors of the stomach, ovaries, colon, rectum bowel, prostate, pancreas, lung, vagina or thyroid gland, sarcoma, glioblastoma, multiple myeloma, cancer of the gastrointestinal tract, neck and head tumor, epidermal hyperproliferation, psoriasis, hyperplasia asia of the prostate gland, epithelial neoplasia, lymphoma, breast carcinoma or leukemia. 4. The use of a compound representing 5- (2,6-dimorpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine, or its stereoisomer, tautomer or pharmaceutically acceptable salt, for the treatment of a disease representing cancer or malignant neoplasm that has become resistant or has1. Применение соединения, представляющего собой 5-(2,6-диморфолин-4-илпиримидин-4-ил)-4-трифторметилпиридин-2-иламин, или его стереоизомера, таутомера или фармацевтически приемлемой соли для лечения заболевания, представляющего собой рак или злокачественное новообразование, которое зависит от приобретенного фосфорилирования и активации протеинкиназы АКТ в ходе лечения ингибитором mTOR, представляющим собой эверолимус.2. Применение по п. 1, где заболевание, представляющее собой рак или злокачественное новообразов
